Impact of Endocannabinoid System Manipulation on Neurodevelopmental Processes Relevant to Schizophrenia

被引:10
|
作者
Zamberletti, Erica [1 ,2 ]
Rubino, Tiziana [1 ,2 ]
机构
[1] Univ Insubria, Dept Biotechnol & Life Sci, Busto Arsizio, Varese, Italy
[2] Univ Insubria, Neurosci Ctr, Busto Arsizio, Varese, Italy
关键词
CLINICAL HIGH-RISK; MATERNAL IMMUNE ACTIVATION; CANNABINOID RECEPTOR GENE; ADOLESCENT THC EXPOSURE; HPA-AXIS FUNCTION; PRENATAL EXPOSURE; CNR1; GENE; ENDOGENOUS CANNABINOIDS; GABAERGIC INHIBITION; COGNITIVE DEFICITS;
D O I
10.1016/j.bpsc.2020.06.013
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The neurodevelopmental hypothesis of schizophrenia has received much support from epidemiological and neuropathological studies and provides a framework to explain how early developmental abnormalities might manifest as psychosis in early adulthood. According to this theory, the onset of schizophrenia is likely the result of a complex interplay between a genetic predisposition and environmental factors whose respective influence might contribute to the etiology and progression of the disorder. The two most sensitive windows for neurodevelopment are the prenatal/ perinatal and the adolescent windows, both of which are characterized by specific processes impinging upon brain structure and functionality, whose alterations may contribute to the onset of schizophrenia. An increasing number of articles suggest the involvement of the endocannabinoid system in the modulation of at least some of these processes, especially in the prenatal/perinatal window. Thus, it is not surprising that disturbing the physiological role of endocannabinoid signaling in these sensitive windows might alter the correct formation of neuronal networks, eventually predisposing to neuropsychiatric diseases later in life. We review the most recent preclinical studies that evaluated the impact of endocannabinoid system modulation in the two sensitive developmental windows on neurodevelopmental processes that possess a specific relevance to schizophrenia.
引用
收藏
页码:616 / 626
页数:11
相关论文
共 50 条
  • [21] Endocannabinoid system: Potential novel targets for treatment of schizophrenia
    Saito, Atsushi
    Ballinger, Michael D. L.
    Pletnikov, Mikhail V.
    Wong, Dean F.
    Kamiya, Atsushi
    NEUROBIOLOGY OF DISEASE, 2013, 53 : 10 - 17
  • [22] A LONGITUDINAL EXAMINATION OF THE NEURODEVELOPMENTAL IMPACT OF PRENATAL IMMUNE ACTIVATION IN MICE REVEALS PRIMARY DEFECTS IN DOPAMINERGIC DEVELOPMENT RELEVANT TO SCHIZOPHRENIA
    Vuillermot, Stephanie
    Feldon, Joram
    Meyer, Urs
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 276 - 276
  • [23] A Longitudinal Examination of the Neurodevelopmental Impact of Prenatal Immune Activation in Mice Reveals Primary Defects in Dopaminergic Development Relevant to Schizophrenia
    Vuillermot, Stephanie
    Weber, Liz
    Feldon, Joram
    Meyer, Urs
    JOURNAL OF NEUROSCIENCE, 2010, 30 (04): : 1270 - 1287
  • [24] A prospective cohort study of neurodevelopmental processes in the genesis and epigenesis of schizophrenia
    Cannon, TD
    Rosso, IM
    Bearden, CE
    Sanchez, LE
    Hadley, T
    DEVELOPMENT AND PSYCHOPATHOLOGY, 1999, 11 (03) : 467 - 485
  • [25] Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or Δ9-tetrahydrocannabinol (THC)
    Bossong, Matthijs G.
    Jansma, J. Martijn
    Bhattacharyya, Sagnik
    Ramsey, Nick F.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2014, 52 : 53 - 69
  • [26] Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
    Leweke, F. Markus
    Mueller, Juliane K.
    Lange, Bettina
    Fritze, Stefan
    Topor, Cristina E.
    Koethe, Dagmar
    Rohleder, Cathrin
    CNS DRUGS, 2018, 32 (07) : 605 - 619
  • [27] MODULATION OF THE ENDOCANNABINOID SYSTEM AS A POTENTIAL NEW TARGET IN THE TREATMENT OF SCHIZOPHRENIA
    Leweke, F. Markus
    Hellmich, Martin
    Pahlisch, Franziska
    Kranaster, Laura
    Koethe, Dagmar
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S47 - S47
  • [28] Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions
    Zador, Ferenc
    Nagy-Grocz, Gabor
    Kekesi, Gabriella
    Dvoracsko, Szabolcs
    Szucs, Edina
    Tomboly, Csaba
    Horvath, Gyongyi
    Benyhe, Sandor
    Vecsei, Laszlo
    MOLECULES, 2019, 24 (20):
  • [29] Activation of the endocannabinoid system in schizophrenia: A compensatory mechanism of subclinical inflammation?
    Misiak, Blazej
    Bielawski, Tomasz
    Samochowiec, Jerzy
    Samochowiec, Agnieszka
    Fleszar, Mariusz G.
    Fortuna, Paulina
    Kosyk, Bogna
    Frydecka, Dorota
    SCHIZOPHRENIA RESEARCH, 2023, 252 : 67 - 68
  • [30] Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia
    Ferretjans, Rodrigo
    de Campos, Salvina Maria
    Ribeiro-Santos, Rafael
    Guimaraes, Fernanda Carneiro
    de Oliveira, Keliane
    Alves Cardoso, Ana Cecilia
    Araujo, Marcio Sobreira
    Teixeira-Carvalho, Andrea
    Martins-Filho, Olindo Assis
    Teixeira, Antonio L.
    Salgado, Joao V.
    SCHIZOPHRENIA RESEARCH, 2014, 156 (2-3) : 254 - 260